Program
Bcl-2 Inhibitor TQB3909
Also written as “TQB3909 tablets”, “TQB3909 Tablets” and “TQB3909 Tablets + Azacitidine”.
In Sino Biopharmaceutical’s pipeline, BCL-2抑制剂
. Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Primary Myelofibrosis · Hematologic Neoplasms · Breast Neoplasms, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 85 open or running | phase 3since Aug 4, 2026 | Jul 14, 2021 | Dec 2030phase 3 · NCT07753369 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2021First study: phase 1 study in Advanced Malignant TumorFirst studyNCT04975204 · 126 enrolled · China
- Dec 7, 2022Phase 2 study in Advanced Breast CancerNCT05775575 · 65 enrolled · China
- Jul 17, 2023Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05959694 · 107 planned · China
- Nov 30, 2023Phase 1 study in Advanced Malignant NeoplasmNCT06165822 · 40 planned · China
- Jan 9, 2024Phase 1 study in Hematologic NeoplasmsNCT06211751 · 208 planned · China
- Jan 30, 2024Phase 2 study in Primary MyelofibrosisNCT06245941 · 21 enrolled · China
- May 21, 2025Phase 2 study in Myeloid MalignancyNCT07011186 · 138 planned · China
- Aug 4, 2026Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellPhase 3 reachedNCT07753369 · 128 planned · China
Ahead
- Dec 2030Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07753369
TargetBeta
“BCL-2抑制剂”the company's pipeline, read by Claude · source
Other programs on BCL2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| venetoclaxrule | AbbVie | phase 4 | 83 |
| lacutoclaxrule | Lupeng Pharmaceutical | phase 2 | 4 |
| surzetoclax | AbbVie | phase 2 | 3 |
| 400mg of TQB3909 tablets | Sino Biopharmaceutical | phase 2 | 1 |
| surzetoclax | AbbVie | phase 1 | 2 |
| FXS0683 | Fosun Pharma | phase 1 | 1 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07753369Leukemia, Lymphocytic, Chronic, B-Cell · China | 3 | Not yet recruiting | Dec 2030 | 128 |
| NCT07011186Myeloid Malignancy · China | 2 | Recruiting | Oct 2025 | 138 |
| NCT06245941Primary Myelofibrosis · China | 2 | Terminated | Dec 30, 2025 | 21 |
| NCT06211751Hematologic Neoplasms · China | 1 | Not yet recruiting | Dec 2025 | 208 |
| NCT06165822Advanced Malignant Neoplasm · China | 1 | Not yet recruiting | Jan 2024 | 40 |
| NCT05959694Leukemia, Lymphocytic, Chronic, B-Cell · China | 2 | Recruiting | Dec 2025 | 107 |
| NCT05775575Advanced Breast Cancer · China | 2 | UNKNOWN | Dec 2023 | 65 |
| NCT04975204Advanced Malignant Tumor · China | 1 | UNKNOWN | Dec 2022 | 126 |
How it is read
Names in the registry
- “TQB3909 tablets”, 4 entries
- “TQB3909 Tablets”, 2 entries
- “TQB3909 Tablets + Azacitidine”, 1 entry
- “TQB3909 tablet”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 2 studies
- Primary Myelofibrosis, 1 study
- Hematologic Neoplasms, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.